Filtered By:
Specialty: Cardiology
Condition: Heart Attack
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 446 results found since Jan 2013.
Percutaneous Coronary Intervention for Very Small Vessels With the Use of a Newer-Generation 2.0 mm Drug-Eluting Stent
CONCLUSIONS: Our data suggest that the use of the Onyx 2.0 mm DES to treat CAD in very small vessels (<2.25 mm) is feasible and safe, and the clinical outcomes were similar to those of the Onyx 2.25 mm group.PMID:34224385
Source: The Journal of Invasive Cardiology - July 5, 2021 Category: Cardiology Authors: Hsu-Lung Jen Yao-Chang Wang Tien-Ping Tsao Wei-Hsian Yin Source Type: research
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
CONCLUSIONS: Use of evolocumab robustly lowers LDL-C and is equally efficacious in lowering the risk of cardiovascular events and safe in Asians as it is in others.PMID:33980763 | DOI:10.1253/circj.CJ-20-1051
Source: Circulation Journal - May 13, 2021 Category: Cardiology Authors: Anthony C Keech Kazuma Oyama Peter S Sever Minao Tang Sabina A Murphy Atsushi Hirayama Chen Lu Leslie Tay Prakash C Deedwania Chung-Wah Siu Armando Lira Pineda Donghoon Choi Min-Ji Charng John Amerena Wan Azman Wan Ahmad Vijay K Chopra Terje R Pedersen Ro Source Type: research
Searching for the ideal LDL cholesterol estimating formula
For long, low-density lipoprotein cholesterol (LDL-C) has been considered one of the major therapeutic targets for primary and secondary prevention in cardiovascular (CV) disease. Since more than two decades ago, pivotal trials have demonstrated that LDL-C lowering with statins translates into a log proportional reduction in a vast array of CV events (myocardial infarction, stroke, need for coronary or arterial revascularization), as well as mortality [1]. More recently, similar benefits have been observed with other LDL-C lowering therapies, such as ezetimibe [2] and proprotein covertase subtilisin kexin type 9 (PCSK-9) inhibitors [3].
Source: International Journal of Cardiology - March 9, 2021 Category: Cardiology Authors: Remo Holanda de Mendonca Furtado Tags: Editorial Source Type: research
Evaluation of 1-Year Follow-up of Patients Included in the Registry of Clinical Practice in Patients at High Cardiovascular Risk (REACT)
Conclusions In this large national registry of patients at high cardiovascular risk, risk predictors similar to those of international registries were identified, but medical prescription adherence to evidence-based therapies was inferior and significantly worsened at 1 year. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0)
Source: Arquivos Brasileiros de Cardiologia - February 4, 2021 Category: Cardiology Source Type: research
Rediscovering Brazil: How We Prevent and Treat Cardiovascular Disease
Conclusions In this large national registry of patients at high cardiovascular risk, risk predictors similar to those of international registries were identified, but medical prescription adherence to evidence-based therapies was inferior and significantly worsened at 1 year. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0)
Source: Arquivos Brasileiros de Cardiologia - February 4, 2021 Category: Cardiology Source Type: research
The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH
Key pointsSTRENGTH,1 an industry-sponsored, double-blind, randomized, controlled trial investigated the effects of a carboxylic acid (CA) formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (omega-3 CA) vs. corn oil in 13 078 participants with high cardiovascular (CV) risk, hypertriglyceridaemia, and low levels of high-density lipoprotein cholesterol.Eligible patients were randomized to receive 4 g/day of omega-3 CA or corn oil in addition to standard preventive therapies, including statins (high-intensity in 50%), renin-angiotensin-aldosterone system (RAAS) blockers (in 81%), and antiplatelet agents ...
Source: European Heart Journal - February 1, 2021 Category: Cardiology Source Type: research
Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand.
CONCLUSIONS: The five-drugs comprising OMT were associated with a reduction in all-cause mortality and MACE in patients with ACS. Nevertheless, OMT prescribing remains underused and could be enhanced in the real-world setting.
PMID: 33455848 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - January 14, 2021 Category: Cardiology Authors: Wongsalap Y, Kengkla K, Poolpun D, Saokaew S Tags: J Cardiol Source Type: research
High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study.
CONCLUSIONS: After statin therapy with modestly controlled LDL-C, HDL-C level has little prognostic value in patients with stable CAD.
PMID: 33431716 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - January 13, 2021 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Conclusions: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL did not appear to derive further reduction in the risk of MACE compared to those who achieved LDL-C levels of 25-50 mg/dL. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier: NCT01663402.
PMID: 33438437 [PubMed - as supplied by publisher]
Source: Circulation - January 13, 2021 Category: Cardiology Authors: Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, ODYSSEY OUTCOMES Committees and Investigators Tags: Circulation Source Type: research
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study
Conclusions Larger early LDL-C reduction and more intensive statin therapy after MI were associated with a reduced hazard of all CV outcomes and all-cause mortality. This supports clinical trial data suggesting that earlier lowering of LDL-C after an MI confers the greatest benefit.
Source: European Heart Journal - December 24, 2020 Category: Cardiology Source Type: research
Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: a Systematic Review.
CONCLUSION: After reviewing all the research mentioned in this review, it can be confirmed that hyperlipidemia is a risk factor for stroke and correlated in patients with CVD.
PMID: 33305711 [PubMed - as supplied by publisher]
Source: Current Cardiology Reviews - December 13, 2020 Category: Cardiology Tags: Curr Cardiol Rev Source Type: research
